Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port

Journal of Neuroscience Methods

Volumn 214, Issue 2, 2013, Pages 223-232

  Barua, N U ^a,b   Woolley, M ^a,c   Bienemann, A S ^a   Johnson, D E ^a,c   Lewis, O ^c   Wyatt, M J ^a   Irving, C ^c   O'Sullivan, S ^c   Murray, G ^c   Fennelly, C ^c   Skinner, P ^c   Gill, S S ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

^c RENISHAW PLC   (United Kingdom)

Author keywords

Bone anchored; Convection enhanced delivery; Port; Titanium; Transcutaneous

Indexed keywords

TITANIUM;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CONVECTION ENHANCED DELIVERY; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; EXPERIMENTAL PIG; FEASIBILITY STUDY; NONHUMAN; PRIORITY JOURNAL; TRANSCUTANEOUS BONE ANCHORED PORT;

ANIMALS; BRAIN; CONVECTION; DRUG DELIVERY SYSTEMS; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; INFUSION PUMPS, IMPLANTABLE; SUTURE ANCHORS; SWINE;

EID: 84874704529     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2013.02.007     Document Type: Article

References (48)

1. Arnold A., Caversaccio M.D., Mudry A. Surgery for the bone-anchored hearing aid. Adv Otorhinolaryngol 2011, 71:47-55.
2. Bienemann A., White E., Woolley M., Castrique E., Johnson D.E., Wyatt M., et al. The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery. J Neurosci Methods 2012, 203:284-291.
3. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994, 91:2076-2080.
4. Bogdahn U., Hau P., Stockhammer G., Venkataramana N.K., Mahapatra A.K., Suri A., et al. Targeted therapy for high-grade glioma with the TGF-beta2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol 2011, 13:132-142.
5. Branemark P.I., Albrektsson T. Titanium implants permanently penetrating human skin. Scand J Plast Reconstr Surg 1982, 16:17-21.
6. Bruce J.N., Fine R.L., Canoll P., Yun J., Kennedy B.C., Rosenfeld S.S., et al. Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 2011, 69:1272-1279.
7. Chamberlain M.C., Kormanik P.A., Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg 1997, 87:694-699.
8. Colquitt J., Jones J., Harris P., Loveman E., Bird A., Clegg A., et al. Bone-anchored hearing aids (BAHAs) for people who are bilaterally deaf: a systematic review and economic evaluation. Health Technol Assess 2011, 15:1-200.
9. Colquitt J.L., Loveman E., Baguley D.M., Mitchell T.E., Sheehan P.Z., Harris P., et al. Bone-anchored hearing aids for people with bilateral hearing impairment: a systematic review. Clin Otolaryngol 2011, 36:419-441.
10. de Wolf M.J., Hol M.K., Huygen P.L., Mylanus E.A., Cremers C.W. Clinical outcome of the simplified surgical technique for BAHA implantation. Otol Neurotol 2008, 29:1100-1108.
11. de Wolf M.J., Hol M.K., Mylanus E.A., Cremers C.W. Bone-anchored hearing aid surgery in older adults: implant loss and skin reactions. Ann Otol Rhinol Laryngol 2009, 118:525-531.
12. de Wolf M.J., Hol M.K., Mylanus E.A., Snik A.F., Cremers C.W. Benefit and quality of life after bone-anchored hearing aid fitting in children with unilateral or bilateral hearing impairment. Arch Otolaryngol Head Neck Surg 2011, 137:130-138.
13. de Wolf M.J., Leijendeckers J.M., Mylanus E.A., Hol M.K., Snik A.F., Cremers C.W. Age-related use and benefit of the bone-anchored hearing aid compact. Otol Neurotol 2009, 30:787-792.
14. Ding D., Kanaly C.W., Bigner D.D., Cummings T.J., Herndon J.E., Pastan I., et al. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1 sampson JH. J Neurooncol 2010, 98:1-7.
15. Doshi J., McDermott A.L., Reid A., Proops D. The use of a bone-anchored hearing aid (Baha) in children with severe behavioural problems-the Birmingham Baha programme experience. Int J Pediatr Otorhinolaryngol 2010, 74:608-610.
16. Dun C.A., Faber H.T., de Wolf M.J., Cremers C.W., Hol M.K. An overview of different systems: the bone-anchored hearing aid. Adv Otorhinolaryngol 2011, 71:22-31.
17. Dutt S.N., McDermott A.L., Jelbert A., Reid A.P., Proops D.W. The Glasgow benefit inventory in the evaluation of patient satisfaction with the bone-anchored hearing aid: quality of life issues. J Laryngol Otol Suppl 2002, 7-14.
18. Fitzpatrick N., Smith T.J., Pendegrass C.J., Yeadon R., Ring M., Goodship A.E., et al. Intraosseous transcutaneous amputation prosthesis (ITAP) for limb salvage in 4 dogs. Vet Surg 2011, 40:909-925.
19. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
20. Hudgins R.J., Boydston W.R., Gilreath C.L. Treatment of posthemorrhagic hydrocephalus in the preterm infant with a ventricular access device. Pediatr Neurosurg 1998, 29:309-313.
21. Kang N.V., Pendegrass C., Marks L., Blunn G. Osseocutaneous integration of an intraosseous transcutaneous amputation prosthesis implant used for reconstruction of a transhumeral amputee: case report. J Hand Surg Am 2010, 35:1130-1134.
22. Kells A.P., Eberling J., Su X., Pivirotto P., Bringas J., Hadaczek P., et al. Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF. J Neurosci 2010, 30:9567-9577.
23. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459-466.
24. Liebl A., Hoogma R., Renard E., Geelhoed-Duijvestijn P.H., Klein E., Diglas J., et al. A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusion. Diabetes Obes Metab 2009, 11:1001-1008.
25. Lishner M., Perrin R.G., Field R., Messner H.A., Tuffnell P.G., Elhakim T., et al. Complications associated with Ommaya reservoirs in patients with cancer, the princess margaret hospital experience and a review of the literature. Arch Intern Med 1990, 150:173-176.
26. Love S., Plaha P., Patel N.K., Hotton G.R., Brooks D.J., Gill S.S. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005, 11:703-704.
27. Mangano C., De Rosa A., Desiderio V., d'Aquino R., Piattelli A., De Francesco F., et al. The osteoblastic differentiation of dental pulp stem cells and bone formation on different titanium surface textures. Biomaterials 2010, 31:3543-3551.
28. Masson-Cote L., Masucci G.L., Atenafu E.G., Millar B.A., Cusimano M., Croul S., et al. Long-term outcomes for adult craniopharyngioma following radiation therapy. Acta Oncol 2013, 52:153-158.
29. McDermott A.L., Williams J., Kuo M., Reid A., Proops D. The birmingham pediatric bone-anchored hearing aid program: a 15-year experience. Otol Neurotol 2009, 30:178-183.
30. McDermott A.L., Williams J., Kuo M., Reid A., Proops D. Quality of life in children fitted with a bone-anchored hearing aid. Otol Neurotol 2009, 30:344-349.
31. McDermott A.L., Williams J., Kuo M.J., Reid A.P., Proops D.W. The role of bone anchored hearing aids in children with down syndrome. Int J Pediatr Otorhinolaryngol 2008, 72:751-757.
32. Morrison P.F., Lonser R.R., Oldfield E.H. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 2007, 107:74-83.
33. Mylanus E.A., Beynon A.J., Snik A.F., Cremers C.W. Percutaneous titanium implantation in the skull for the bone-anchored hearing aid. J Invest Surg 1994, 7:327-332.
34. Nyman R., Lundgren D., Nyholm D. Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease. J Vasc Interv Radiol 2009, 20:500-505.
35. Pendegrass C.J., Goodship A.E., Blunn G.W. Development of a soft tissue seal around bone-anchored transcutaneous amputation prostheses. Biomaterials 2006, 27:4183-4191.
36. Pendegrass C.J., Goodship A.E., Price J.S., Blunn G.W. Nature's answer to breaching the skin barrier: an innovative development for amputees. J Anat 2006, 209:59-67.
37. Pendegrass C.J., Gordon D., Middleton C.A., Sun S.N., Blunn G.W. Sealing the skin barrier around transcutaneous implants: in vitro study of keratinocyte proliferation and adhesion in response to surface modifications of titanium alloy. J Bone Joint Surg Br 2008, 90:114-121.
38. Richardson R.M., Kells A.P., Rosenbluth K.H., Salegio E.A., Fiandaca M.S., Larson P.S., et al. Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease. Mol Ther 2011, 19:1048-1057.
39. Robinson S. Neonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment concepts. J Neurosurg 2012, 9:242-258.
40. Runciman W.B., Ilsley A.H., Rutten A.J., Baker D., Fronsko R.R. An evaluation of intravenous infusion pumps and controllers. Anaesth Intensive Care 1987, 15:217-228.
41. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006, 202:497-505.
42. Snik A.F., Mylanus E.A., Proops D.W., Wolfaardt J.F., Hodgetts W.E., Somers T., et al. Consensus statements on the BAHA system: where do we stand at present?. Ann Otol Rhinol Laryngol Suppl 2005, 195:2-12.
43. Sonabend A.M., Stuart R.M., Yun J., Yanagihara T., Mohajed H., Dashnaw S., et al. Prolonged intracerebral convection-enhanced delivery of topotecan with a subcutaneously implantable infusion pump. Neuro Oncol 2011, 13:886-893.
44. Soo G., Tong M.C., Tsang W.S., Wong T.K., To K.F., Leung S.F., et al. hearing system for hearing-impaired postirradiated nasopharyngeal cancer patients: a new indication. Otol Neurotol 2009, 30:496-501.
45. Stalfors J., Tjellstrom A. Skin reactions after BAHA surgery: a comparison between the U-graft technique and the BAHA dermatome. Otol Neurotol 2008, 29:1109-1114.
46. Sundaresan N., Suite N.D. Optimal use of the Ommaya reservoir in clinical oncology. Oncology (Williston Park, N. Y) 1989, 3:15-22. discussion 3.
47. Wallberg E., Granstrom G., Tjellstrom A., Stalfors J. Implant survival rate in bone-anchored hearing aid users: long-term results. J Laryngol Otol 2011, 125:1131-1135.
48. White E., Woolley M., Bienemann A., Johnson D.E., Wyatt M., Murray G., et al. A robust MRI-compatible system to facilitate highly accurate stereotactic administration of therapeutic agents to targets within the brain of a large animal model. J Neurosci Methods 2010, 195:78-87.